Food and Drug Administration, or the FDA, Health Canada and European Medicines Agency, or EMA. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. AEON recently completed a Phase 2 study of ABP-450 for the treatment of cervical dystonia and has an ongoing Phase 2 study of ABP-450 for the treatment of both chronic and episodic migraine. To learn more about AEON and the development of its uniquely positioned therapeutic neurotoxin, visit About AEON BiopharmaĪEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. He consults with numerous pharmaceutical companies involved with medications related to headache disorders, and more details can be found through The Sunshine Act. He has been an active researcher in headache medicine with 26 issued patents for various treatments. He teaches other providers on this procedure nationally and internationally. He helped to develop the injection protocol used in the pivotal migraine trials. His research interests have focused on the use of Botox for migraine. One of his manuscripts was voted the top publication in the Headache journal. He has published widely and has over 100 publications. He is the founding chair of the American Headache Society section on Interventional Procedures for Headache. Blumenfeld is a member and fellow of both the American Academy of Neurology and the American Headache Society. He is Board-certified in Neurology by the American Board of Psychiatry and Neurology and is also certified in Headache Medicine. Blumenfeld is Director of the Los Angeles Headache Center with offices in San Diego and Los Angeles. He completed his Neurology residency at the Longwood Area Harvard program, and has been board certified in Headache Medicine since 2006.ĭr. Tepper received his undergraduate degree cum laude in the study of the nervous system/psychobiology from Yale College, and attended Cornell University Medical College. He also serves on the Governance Committee and Board of Directors of the American Migraine Foundation. He serves on the AHS Education, Exhibits, and Finance Committees. Tepper serves on the Executive Board of Directors and is the Corporate Liaison for the American Headache Society. He has published more than 470 peer-reviewed manuscripts, editorials, and books on Headache Medicine. He was Editor-in-Chief of the journal Headache Currents and Associate Editor for the journal Headache from 2012-2020. Tepper was Director of the Scottsdale Headache Symposium CME course of the American Headache Society from 2008 to 2020. He is Director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Tepper is a Professor of Neurology at the Geisel School of Medicine at Dartmouth College in Hanover, New Hampshire. To register for the event, please click here.ĭr. Additionally, AEON’s leadership team will provide an update on clinical developments and the predicted timeline of future product development.Ī live question and answer session will follow the formal presentations. The event will highlight the differences between monotherapy and combination therapy in the context of migraine treatments. Blumenfeld, MD, Director of the Los Angeles Headache Center, to discuss the past, present, and potential future treatment landscapes for migraine, along with AEON’s innovative uses of botulinum toxin for the treatment of debilitating medical conditions. Tepper, MD, Director of the Dartmouth Headache Center at Dartmouth-Hitchcock Medical Center, and Andrew M. The virtual KOL event will feature presentations by Stewart J. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced today that it will host a key opinion leader (KOL) webinar on the past, present, and potential future treatments for migraine using botulinum toxin on Friday, Februat 11:00 a.m. 14, 2023 (GLOBE NEWSWIRE) - AEON Biopharma, Inc.
0 Comments
Leave a Reply. |